GlassScriptPhysician profile
Keith R Lemay
NPI 1922379759
$1,195.73
in general payments reported to CMS, 2019-2025
23 companies · $660 in 2025
The $660 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.25 · 2023: $158 · 2024: $315 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $137.84 | 2025 | Attruby |
| Abbvie INC. | $129.27 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $85.92 | 2025 | |
| Pfizer INC. | $78.13 | 2024-2025 | |
| Glaxosmithkline, LLC. | $76.80 | 2025 | Trelegy Ellipta, Arexvy |
| Xeris Pharmaceuticals, INC. | $71.31 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $69.09 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $62.25 | 2021 | |
| Stryker Corporation | $58.35 | 2023 | Hoffmann, Gamma, Augment Injectable |
| Lilly USA, LLC | $52.18 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $52.02 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $48.47 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $46.19 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.56 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $33.14 | 2025 | Sapien 3 Ultra Resilia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $30.08 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.75 | 2024 | |
| Sumitomo Pharma America, INC. | $22.35 | 2025 | Gemtesa |
| Philips North America LLC | $22.24 | 2024 | (Cm9) Amb Mon & Diag Und |
| Abbott Laboratories | $17.63 | 2024 | Eterna |
| Exact Sciences Corporation | $15.96 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.83 | 2023 | Quviviq |
| Tactile Systems Technology INC | $14.37 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lemay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.